Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient.
Intern Med
; 61(10): 1561-1565, 2022.
Article
in English
| MEDLINE | ID: covidwho-1847021
ABSTRACT
Although there is a great demand for increased coronavirus disease 2019 (COVID-19) vaccination worldwide, rare side effects of the vaccine in susceptible individuals are attracting attention. We recently treated a patient with type 1 diabetes who had HLA-A*240201/A*020101, B*5401/B*5601, DRB1*0405/DRB1*0405, DPB1*0501/DPB1*0501 and DQB1*0401/DQB1*040 and developed Graves' disease soon after the administration of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. While causal relationships between vaccinations and adverse events are difficult to discern due to both confounding and masking factors, our findings suggest that attention to possible adjuvant-related endocrinological diseases in certain individuals receiving SARS-CoV-2 vaccines is appropriate.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Graves Disease
/
Diabetes Mellitus, Type 1
/
COVID-19
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Intern Med
Journal subject:
Internal Medicine
Year:
2022
Document Type:
Article
Affiliation country:
Internalmedicine.9231-21
Similar
MEDLINE
...
LILACS
LIS